2100 Powell Street
About Dynavax Technologies
We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.
367 articles with Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the third quarter ended September 30, 2019.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Hundreds lose their jobs as companies close facilities and shift business focuses.
Dynavax plans to step away from immuno-oncology development and will lay off 37% of its staff as a result.
Asthma drug failed to show a statistically clinical improvement in controlling asthma, Dynavax said.
Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Feb. 5, 2018
These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $16.85 per share.
Dynavax Announces HEPLISAV-B is Now Available in the United States for the Prevention of Hepatitis B in Adults
HEPLISAV-B can now be ordered through a network of distributors, which will broaden over the next few weeks.
Dynavax granted stock options to purchase shares of Dynavax's common stock to the new employees with an exercise price of $18.40 per share.
The FDA approved Dynavax's Heplisav-B, it's first new hepatitis B vaccine in the U.S. in more than 25 years.
Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at December 31, 2016.
Here's a closer look at six drugs facing FDA decisions in November.
Dynavax Initiates Clinical Trial In Non-Small Cell Lung Cancer With A Novel Inhaled TLR9 Agonist In Combination With Anti-PD-1 Therapy
Dynavax Technologies Corporation announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC).
Dynavax Announces Exercise In Full Of Over-Allotment Option And Completion Of Public Offering Of Common Stock